Bayer Stock Forecast for 2022 - 2025 - 2030
Updated on 09/27/2022
Bayer Stock Forecast and Price Target
According to fourteen esteemed experts, the average price target for Bayer to reach this year is 79.50€, with a potential upside of approximately 64.36%. This prediction is based on a high estimate of 106.00€ and a low estimate of 37.06€. If you want to invest in BAYN stock, you might also want to take a look at how its competitors are doing.
64.36% Upside
Bayer Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Price has grown by 9.60%, rising from 57.62€ to 63.15€. For next year, analysts predict Fair Value of 73.82€, which would mean an increase of 16.90%. Over the next nine years, experts predict that Bayer's Fair Value will grow at a rate of 2.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$141.21 | Buy/Sell | $164.23 | 10.47% |
| COST Stock Forecast | Costco Wholesale | Outperform |
13
|
$480.30 | Buy/Sell | $565.43 | 17.11% |
| DHR Stock Forecast | Danaher | Outperform |
16
|
$262.66 | Buy/Sell | $321.60 | 23.73% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$99.84 | Buy/Sell | $128.88 | 26.20% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£99.33 | Buy/Sell | £136.08 | 43.33% |
Bayer Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Revenue has grown by 19.97%, rising from 36.74€B to 44.08€B. For next year, analysts predict Revenue of 48.75€B, which would mean an increase of 10.59%. Over the next nine years, experts predict that Bayer's Revenue will grow at a rate of 16.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$70.15 | Buy/Sell | $79.05 | 18.32% |
| AMGN Stock Forecast | Amgen | Hold |
9
|
$226.87 | Buy/Sell | $246.51 | 12.40% |
| DE Stock Forecast | Deere & | Outperform |
11
|
$332.24 | Buy/Sell | $402.13 | 22.20% |
.jpg)
Bayer Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Dividend per Share has decreased by 28.57%, going from 2.80€ to 2.00€. For next year, analysts predict Dividend per Share of 2.22€, which would mean an increase of 11.00%. Over the next nine years, experts predict that Bayer's Dividend per Share will grow at a rate of 20.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
16
|
$284.81 | Buy/Sell | $228.01 | -22.67% |
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$62.34 | Buy/Sell | $69.65 | 13.89% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$231.64 | Buy/Sell | $278.08 | 20.88% |
Bayer Free Cash Flow Forecast for 2022 - 2025 - 2030
Bayer's Free Cash Flow has decreased by 53.46% In the last three years, from 5.32€B to 2.48€B. In the next year, analysts believe that Free Cash Flow will reach 3.54€B – an increase of 42.91%. For the next nine years, experts predict that Bayer's Free Cash Flow will grow at a rate of 122.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CL Stock Forecast | Colgate-Palmolive | Outperform |
18
|
$75.00 | Buy/Sell | $82.26 | 9.33% |
| GSK Stock Forecast | GSK | Outperform |
16
|
£13.25 | Buy/Sell | £16.08 | 43.02% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$57.61 | Buy/Sell | $62.59 | 21.51% |
Bayer Net Income Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's Net Income has decreased from 1.70€B to 1000.00€M – a 41.00% drop. In the next year, analysts believe that Net Income will reach 7.47€B – an increase of 646.84%. For the next nine years, the forecast is for Net Income to grow by 557.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
11
|
39.81€ | Buy/Sell | 78.27€ | 38.16% |
| DOW Stock Forecast | Dow | Hold |
11
|
$43.39 | Buy/Sell | $73.11 | 26.76% |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$195.75 | Buy/Sell | $242.78 | 16.22% |
Bayer EBITDA Forecast for 2022 - 2025 - 2030
Bayer's EBITDA has seen impressive growth In the last three years, rising from 7.15€B to 8.42€B – a growth of 17.89%. In the next year, analysts believe that EBITDA will reach 12.89€B – an increase of 53.04%. For the next nine years, the forecast is for EBITDA to grow by 137.66%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$54.91 | Buy/Sell | $69.92 | 25.66% |
| GIVN Stock Forecast | Givaudan | Hold |
18
|
CHF2.95k | Buy/Sell | CHF4.11k | 20.60% |
| DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$50.05 | Buy/Sell | $76.56 | 47.85% |
Bayer EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's EBIT has grown by 68.01%, rising from 4.26€B to 7.15€B. For the next year, analysts predict that EBIT will reach 8.46€B – an increase of 18.27%. Over the next nine years, experts believe that Bayer's EBIT will grow at a rate of 194.78%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.89k | Buy/Sell | ¥0.00 | 27.05% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$197.39 | Buy/Sell | $209.00 | 21.33% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
101.00€ | Buy/Sell | 102.71€ | 10.89% |
Bayer EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Bayer's EPS has grown by 9.60%, rising from 5.94€ to 6.51€. For next year, analysts predict EPS of 7.61€, which would mean an increase of 16.90%. Over the next nine years, experts predict that Bayer's EPS will grow at a rate of 2.76%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.45k | Buy/Sell | kr2.84k | 12.11% |
| SGO Stock Forecast | Compagnie de Saint-Gobain | Outperform |
18
|
37.49€ | Buy/Sell | 71.19€ | 96.05% |
| CHD Stock Forecast | Church & Dwight | Hold |
11
|
$75.26 | Buy/Sell | $90.41 | 18.39% |
.jpg)